Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03327909 · ClinicalTrials.gov registry record · NA

Timing of Antihypertensive Medications on Key Outcomes in Hemodialysis

A NA study of Blood Pressure and ESRD, sponsored by Stanford University.

Completed
Registry status
NA
Development phase
131
Enrollment target
2
Study locations

NCT03327909 is a NA study of Blood Pressure and ESRD that has completed, run by Stanford University. The registered enrollment target is 131 participants, below the 286-participant average among 101 other Blood Pressure trials with a reported enrollment target (54% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03327909, a NA study of Blood Pressure and ESRD, has completed, sponsored by Stanford University.

COMPLETED
Registry status
NA
Development phase
131 participants
Enrollment target
2
Study locations

Study Summary

For patients with kidney failure requiring hemodialysis treatment, sometimes the blood pressure will drop too low during dialysis. In an effort to prevent that from occurring, patients are frequently told to skip doses of their blood pressure medications. However, whether this actually prevents blood pressure drops during dialysis, and whether it may cause more uncontrolled high blood pressure is unknown. TAKE-HOLD will study the effect of taking or holding blood pressure medication on blood pressure for patients on hemodialysis.

Interventions

  • BEHAVIORAL TAKE vs. HOLD

Study Locations (2)

California

  • Satellite Health Care - Menlo Park
  • Satellite Health Care - San Carlos

Trial Details

FieldValue
Enrollment Target 131 participants
Start Date 2018-07-16
Est. Completion 2019-12-14
Phase NA

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT03327909

The ClinicalTrials.gov registry entry for NCT03327909 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 286-participant average among 101 other Blood Pressure trials with a reported enrollment target (54% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Blood Pressure appearing as the primary indexed condition, and to 1 intervention - of which TAKE vs. HOLD is the first listed.

NCT03327909 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03327909 about?

NCT03327909 is a clinical study titled "Timing of Antihypertensive Medications on Key Outcomes in Hemodialysis". For patients with kidney failure requiring hemodialysis treatment, sometimes the blood pressure will drop too low during dialysis. In an effort to prevent that from occurring, patients are frequently told to skip doses of their blood pressure medications. However, whether this actually prevents bloo...

What is the current status of trial NCT03327909?

This trial is currently completed. It is a NA study. The enrollment target is 131 participants. The study started on 2018-07-16. Estimated completion is 2019-12-14.

What conditions does trial NCT03327909 study?

This clinical trial studies the following conditions: Blood Pressure, ESRD, Hemodialysis Complication.

What interventions are being tested in trial NCT03327909?

The interventions under investigation include: TAKE vs. HOLD (BEHAVIORAL).

Who is sponsoring clinical trial NCT03327909?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03327909 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Blood Pressure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.